Trials / Completed
CompletedNCT03785145
MT10109L in the Treatment of Lateral Canthal Lines
A Multicenter, Double-blind, Randomized, Placebo-controlled, Parallel-group Study to Evaluate the Safety and Efficacy of MT10109L (NivobotulinumtoxinA) for the Treatment of Lateral Canthal Lines
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 235 (actual)
- Sponsor
- Medy-Tox · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the safety and efficacy of MT10109L in the treatment of lateral canthal lines (LCL) in participants with moderate to severe LCL.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | MT10109L | MT10109L will be injected into the LCL. |
| DRUG | Placebo | Placebo will be injected into the LCL. |
Timeline
- Start date
- 2018-12-20
- Primary completion
- 2020-02-27
- Completion
- 2021-01-25
- First posted
- 2018-12-24
- Last updated
- 2023-10-05
- Results posted
- 2023-10-05
Locations
14 sites across 3 countries: United States, Russia, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03785145. Inclusion in this directory is not an endorsement.